Advice

following a full submission

teriflunomide (Aubagio®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of adults with relapsing remitting multiple sclerosis (MS).

SMC restriction: as an alternative to treatment with interferon beta or glatiramer acetate. Teriflunomide is not expected to be used for the treatment of patients with highly active disease.

In two phase III, randomised, double-blind, placebo-controlled, parallel-group studies in adult patients with relapsing MS, teriflunomide significantly reduced the annualised relapse rate.  In a phase III, randomised, single-blind, parallel-group study, teriflunomide showed similar efficacy to interferon beta.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of teriflunomide. This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

Download detailed advice177KB (PDF)

Download

Medicine details

Medicine name:
teriflunomide (Aubagio)
SMC ID:
940/14
Indication:
Treatment of adults with relapsing remitting multiple sclerosis (MS).
Pharmaceutical company
Genzyme Therapeutics Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published:
10 March 2014